ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Serplulimab (Hetronifly)

Small cell lung cancer (SCLC) Hetronifly in combination with carboplatin and etoposide is indicated for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC). Non-small cell lung carcinoma (NSCLC) Hetronifly in combination with carboplatin and pemetrexed is indicated for the first-line treatment… Show the full indication

Small cell lung cancer (SCLC) Hetronifly in combination with carboplatin and etoposide is indicated for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC). Non-small cell lung carcinoma (NSCLC) Hetronifly in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult non-squamous NSCLC patients with no EGFR, ALK or ROS1 positive mutations and who have: locally advanced NSCLC who are not candidates for surgery or radiotherapy, or metastatic NSCLC. Oesophageal squamous cell carcinoma (OSCC) Hetronifly in combination with fluoropyrimidine- and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS ≥ 5.

CHMP opinion 19 Sept 2024 → EU licence 3 Feb 2025 · Accord Healthcare S.L.U.

Research

Oncology · Lancet · 2026-06-01

In 588 patients with PD-L1-positive (CPS ≥5) resectable gastric or GOJ adenocarcinoma, perioperative serplulimab with neoadjuvant SOX improved event-free survival vs perioperative SOX (median not reached vs 35·9 months; HR 0·73), with less grade ≥3 toxicity (47% vs 59%).

RCTn = 588
Shen et al. Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
Respiratory · Lancet Respir Med · 2025-12-04

In a phase 3 trial of 636 patients with advanced non-squamous NSCLC, first-line serplulimab plus chemotherapy improved median PFS vs chemotherapy alone (11.0 vs 5.6 months; HR 0.55); adding HLX04 gave no further benefit (HR 0.86). Serious related events: 37% vs 24%.

RCTn = 636
Wang et al. First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.